Effect of a High Protein Diet And/or Resistance Exercise on the Preservation of Fat Free Mass During Weight Loss in Overweight and Obese Older Adults: a Randomized Controlled Trial
Overview
Authors
Affiliations
Background: Intentional weight loss in obese older adults is a risk factor for accelerated muscle mass loss. We investigated whether a high protein diet and/or resistance exercise preserves fat free mass (FFM) during weight loss in overweight and obese older adults.
Methods: We included 100 overweight and obese adults (55-80 year) in a randomized controlled trial (RCT) with a 2 × 2 factorial design and intention-to-treat analysis. During a 10-week weight loss program all subjects followed a hypocaloric diet. Subjects were randomly allocated to either a high protein (1.3 g/kg body weight) or normal protein diet (0.8 g/kg), with or without a resistance exercise program 3 times/week. FFM was assessed by air displacement plethysmography.
Results: At baseline, mean (±SD) BMI was 32 ± 4 kg/m. During intervention, protein intake was 1.13 ± 0.35 g/kg in the high protein groups vs. 0.98 ± 0.29 in the normal protein groups, which reflects a 16.3 ± 5.2 g/d higher protein intake in the high protein groups. Both high protein diet and exercise did not significantly affect change in body weight, FFM and fat mass (FM). No significant protein*exercise interaction effect was observed for FFM. However, within-group analysis showed that high protein in combination with exercise significantly increased FFM (+0.6 ± 1.3 kg, p = 0.011).
Conclusion: A high protein diet, though lower than targeted, did not significantly affect changes in FFM during modest weight loss in older overweight and obese adults. There was no significant interaction between the high protein diet and resistance exercise for change in FFM. However, only the group with the combined intervention of high protein diet and resistance exercise significantly increased in FFM.
Trial Registration: Dutch Trial Register, number NTR4556, date 05-01-2014.
Optimised Skeletal Muscle Mass as a Key Strategy for Obesity Management.
Barber T, Kabisch S, Pfeiffer A, Weickert M Metabolites. 2025; 15(2).
PMID: 39997710 PMC: 11857510. DOI: 10.3390/metabo15020085.
Romano B, de Araujo I, Ribeiro M, Parreiras E Silva L, Dick-de-Paula I, Fukada S JBMR Plus. 2024; 9(1):ziae150.
PMID: 39677928 PMC: 11646085. DOI: 10.1093/jbmrpl/ziae150.
Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity.
Mechanick J, Butsch W, Christensen S, Hamdy O, Li Z, Prado C Obes Rev. 2024; 26(1):e13841.
PMID: 39295512 PMC: 11611443. DOI: 10.1111/obr.13841.
Research advances in the therapy of metabolic syndrome.
Lin Z, Sun L Front Pharmacol. 2024; 15:1364881.
PMID: 39139641 PMC: 11319131. DOI: 10.3389/fphar.2024.1364881.
Medical weight loss in older persons with obesity.
Gavras A, Batsis J Clin Obes. 2024; 14(5):e12684.
PMID: 38924367 PMC: 11570349. DOI: 10.1111/cob.12684.